Abstract:The recent coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2), has led to an unprecedented global health crisis that is still having profound impact on societies, economies and healthcare systems worldwide. Although SARS-CoV-2 is no longer the destructive pathogen it was at the beginning of the pandemic, the infection has now reached endemic proportions and continues to harm the most vulnerable segments of the population (i.e. elderly, immunocompromised individuals, patients with multiple comorbidities). Thus, irrespective of recent claims, the pandemic is not completely over, and we will need to find a "new normal" to live with this coronavirus by limiting the immediate impact of an acute infection on human health and the consequences that long-COVID (also known as "post-COVID" syndrome) may cause on the medium/long-term on health and fitness [1, 2]. It is precisely for this reason that the journal is still publishing some contributions on COVID-19, and will predictably continue to do so for the foreseeable future. Some of these articles are comprised in this issue of the journal. The first of these contributions, published by Lane et al. [3], describes a high-throughput peptide immunoaffinity liquid chromatography-mass spectrometry (SISCAPA-LC-MS) assay using polyclonal capture antibodies to detect and measure the nucleoprotein (N) of SARS-CoV-2 in human saliva. In the author's hands, the method exhibited acceptable specificity (i.e. 89.8 %), counterbalanced by a considerably poor sensitivity (i.e. 37.7 %), making its diagnostic performance even lower than that of some high-throughput SARS-CoV-2 antigen immunoassays currently available on the market [4]. In the second article, published by Ge et al. [5], a different approach for SARS-CoV-2 detection is presented, based on assessment of subgenomic RNA (sgRNA). The major advantage of this assay over standard molecular biology techniques that measure viral RNA is that sgRNA is only produced during virus replication and can hence be used as a valuable surrogate for individual infectivity. Therefore, notwithstanding the large heterogeneity of detection techniques, current evidence suggests that sgRNA could be used as a marker of viral replication, allowing the identification of individuals that are still spreading viable viruses, along with establishment of more appropriate treatments and/or isolation strategies. The following article by Schoenmakers et al. [6] examined the clinical significance of measuring a simple score called CoLab, based on age and ten laboratory tests (i.e., erythrocytes, leukocytes, eosinophilic granulocytes, basophilic granulocytes, bilirubin, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyltransferase, albumin and c-reactive protein) in patients with severe forms of COVID-19 who had to be admitted to the intensive care unit (ICU). The authors found a significant association between the CoLab score and viral load on admission and, more importantly, patient de-isolation could be predicted by CoLab, as a change in its score was significantly associated with gradual reduction in viral load. Since high viral load is a significant predictor of illness severity and unfavorable outcome in COVID-19 patients, the CoLab score could therefore be considered as a potential tool for prognostication and clinical management of patients with severe COVID-19 disease. In line with the previous article, Mink et al. [7] conducted a systematic literature review to decipher the potential prognostic value of anti-SARS-CoV-2 antibodies. The result of the literature search is remarkable, in that the authors included 33 studies with over 30 million individuals in their analysis. Overall, a highly significant association was found between anti-SARS-CoV-2 antibodies and lower risk of SARS-CoV-2 infection and better outcomes (including mortality). It was concluded that measurement of anti-SARS-CoV-2 antibodies may be a useful tool for timely identification of patients at higher risk of infection and/or clinical deterioration who may require booster vaccination or more aggressive therapeutic treatment. The search for reliable predictors of unfavorable clinical course of COVID-19 disease continues with the article published by Krčmová and colleagues [8]. In brief, the authors collected urine and blood for one week from 108 patients hospitalized with COVID-19 (55 vaccinated; 51 %), and used LC-MS/MS assays to measure neopterin, kynurenine, tryptophan, fat-soluble vitamins, and biomarkers of DNA damage. Overall, neopterin, kynurenine and the kynurenine/tryptophan ratio were found to decrease significantly between 4 and 7 days after hospitalization, but their concentration remained elevated in patients with unfavorable clinical course or post-COVID syndrome. In addition, significantly decreased levels of vitamins A, E and D were found in -Abstract Truncated-

Trends of common laboratory biomarkers after SARS-CoV-2 infection

Biomarkers in long COVID-19: A systematic review

Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19

SARS-CoV-2 is here to stay: do not lower our guard

Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort

Time Course of Biochemical and Metabolic Parameters During and After COVID-19

Temporal changes in laboratory markers of survivors and non-survivors of adult inpatients with COVID-19

Long-term infection of SARS-CoV-2 changed the body's immune status

Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection

Effectiveness of laboratory tests in tracking severely COVID-19 infections

Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

Prognosis of COVID-19: Changes in laboratory parameters

Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients—A Prospective Multicenter Cross-Sectional Study

Effects of SARS-CoV-2 Infection on Attention, Memory, and Sensorimotor Performance

Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study

Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort

Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection

Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection

Changes in memory and cognition during the SARS-CoV-2 human challenge study